62
Participants
Start Date
January 17, 2017
Primary Completion Date
August 27, 2019
Study Completion Date
March 16, 2021
cediranib and olaparib
"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
Research Site, New York
Research Site, Rochester
Research Site, Towson
Research Site, Winston-Salem
Research Site, Charlotte
Research Site, Newnan
Research Site, Augusta
Research Site, Orlando
Research Site, Miami
Research Site, Miami
Research Site, Mobile
Research Site, Knoxville
Research Site, Fort Wayne
Research Site, Billings
Research Site, Westwood
Research Site, Covington
Research Site, West Hollywood
Research Site, Downey
Research Site, San Diego
Research Site, Orange
Research Site, San Francisco
Research Site, Greenbrae
Research Site, Seattle
Research Site, Anchorage
Research Site, Boston
Lead Sponsor
Myriad Genetic Laboratories, Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
AstraZeneca
INDUSTRY